IP Library Granted Patent US 9,610,303
Granted Patent B2
US 9,610,303 · App. 11/818,741 · Granted Apr 4, 2017

Glucan preparations

Inventors: Andrew Magee (Maynard, MA); James Rolke (Woburn, MA); Ren-der Yang (Shrewsburg, MA)
Assignee: BIOTHERA, INC.
A61K31/716C08B37/0024C08L5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,610,303
App. No.
11/818,741
Granted
Apr 4, 2017
Kind
B2
Abstract

Particulate β-glucan is solubilized at elevated pressure and temperature to form soluble β-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent.

Claims (24)

1. A process for producing underivatized, soluble β-glucan derived from Saccharomyces cerevisiae and having immunostimulating properties and an average molecular weight between about 120,000 Da and about 205,000 Da; soluble β-glucan having a molecular weight over 380,000 Da in an amount less than or equal to 10%; and β-glucan having a molecular weight under 25,000 Da in an amount less than or equal to 17%, the process comprising:

applying pressure to a suspension comprising particulate β-glucan and acetic acid; and heating the suspension for a time sufficient to form the soluble β-glucan, wherein the suspension is buffered to a pH of about 3.6, and wherein the underivatized, soluble β-glucan is not treated with caustic solution during the process.

2. The process of claim 1 and further comprising:

clarifying the soluble β-glucan.

3. The process of claim 2 wherein the soluble β-glucan is clarified by centrifugation, filtration or a combination thereof.

4. The process of claim 1 wherein the suspension is in a vessel in which substantially all oxygen is removed.

5. The process of claim 4 wherein the oxygen is removed by purging the vessel with nitrogen.

6. The process of claim 1 and further comprising: separating the soluble β-glucan into fractions based on molecular weight.

7. The process of claim 6 wherein the soluble β-glucan is separated by chromatography.

8. A composition comprising:

underivatized, soluble β-glucan derived from Saccharomyces cerevisiae and having immunostimulatory properties and an average molecular weight between about 120,000 Da and about 205,000 Da;

soluble β-glucan having a molecular weight over 380,000 Da in an amount less than or equal to 10%; and β-glucan having a molecular weight under 25,000 Da in an amount less than or equal to 17%,

wherein the underivatized, soluble β-glucan is prepared by applying pressure to a suspension comprising particulate β-glucan and acetic acid, and heating the suspension for a time sufficient to form the soluble β-glucan, wherein the suspension is buffered to a pH of about 3.6, and wherein the underivatized, soluble β-glucan is not treated with caustic solution during preparation.

9. The composition of claim 8 where the underivatized, soluble β-glucan forms a triple helix aggregate having a molecular weight between about 25,000 Da and about 380,000 Da.

10. The composition of claim 8 where the underivatized, soluble β-glucan is prepared by applying about 35 PSI of pressure to the suspension.

11. The composition of claim 8 where the underivatized, soluble β-glucan is prepared by heating the suspension to about 135° C.

12. The composition of claim 8 where the underivatized, soluble β-glucan has a molecular weight over 380,000 Da in an amount of from 4% to 8%.

13. The composition of claim 8 where the underivatized, soluble β-glucan has a molecular weight under 25,000 Da in an amount of from 8% to 13%.

14. The composition of claim 8 where the underivatized, soluble β-glucan has a reducing sugar of from 1.0% to 1.1% of total hexose.

15. The composition of claim 8 where the suspension is heated in the presence of about 0.61 g of sodium acetate and about 5.24 ml glacial acetic acid per liter of the suspension.

16. The composition of claim 8 where the underivatized, soluble β-glucan is prepared in the presence of nitrogen.

17. The composition of claim 8 where the preparation of the underivatized, soluble β-glucan does not use formic acid or sulfuric acid.

18. The composition of claim 8 where the soluble β-glucan is purified by chromatography.

19. The composition of claim 8 where the soluble β-glucan is purified by hydrophobic interaction chromatography.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2020
From: BIOTHERA, INC.
To: HIBERCELL, INC.
Reel/Frame 053544/0350 →
RELEASE OF SECURITY INTEREST Recorded Apr 2, 2020
From: MIDCAP FINANCIAL SERVICES, LLC
To: BIOTHERA, INC.; LIFE SOURCE BASICS INC.; BIOTHERA HEALTH INC.
Reel/Frame 052297/0045 →
RELEASE OF SECURITY INTEREST Recorded May 29, 2015
From: QUEENWOOD CAPITAL PARTNERS, LLC
To: BIOTHERA HOLDING CORP. FORMERLY KNOWN AS BIOPOLYMER ENGINEERING, INC. DBA BIOTHERA
Reel/Frame 035797/0659 →
SECURITY INTEREST Recorded Apr 8, 2015
From: BIOTHERA, INC.; LIFE SOURCE BASICS INC.; BIOTHERA HEALTH INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 035361/0929 →
CHANGE OF NAME Recorded May 23, 2011
From: BIOPOLYMER ENGINEERING, INC. D/B/A BIOTHERA
To: BIOTHERA, INC.
Reel/Frame 026325/0671 →
SECURITY AGREEMENT Recorded Oct 6, 2008
From: BIOPOLYMER ENGINEERING, INC. (D/B/A BIOTHERA)
To: QUEENWOOD CAPITAL PARTNERS LLC
Reel/Frame 021630/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2008
From: MAGEE, ANDREW; ROLKE, JAMES; YANG, REN-DER
To: BIOPOLYMER ENGINEERING, INC. DBA BIOTHERA
Reel/Frame 020441/0243 →
Continuity (2)
Provisional Application 60813971 · Jun 15, 2006
Related Publication 20080103112A1 · May 1, 2008